Open in interactive viewer → charts, metric popovers & call review

Lucid Finally Got Paid by Medicare — and the Stock Fell 58%

The reimbursement breakthrough arrived through a Texas contractor and a claim-by-claim pathway, not the long-promised MolDx LCD. The equity is still priced as an option, not a business.
LUCD · Earnings Call · 2026-11-12

The win that isn't the one they sold

For roughly a year, Lucid Diagnostics ran a one-variable story: wait for the MolDx local coverage determination. On the March call the CEO was categorical — “Medicare is coming. It is a matter of when, not if.” — Dr. Lishan Aklog, Chairman and CEO · 2026-03-26 By November 2025 the company was guiding investors to a draft LCD by year-end. By May and again by August, the draft was still stuck in a CMS administrative backlog. Then this quarter Lucid solved the problem sideways. The Medicare contractor with jurisdiction over its Texas laboratory — Novitas, which sits outside the MolDx program — began adjudicating Medicare claims as reasonable and necessary in late September and paying them in October. The formal term is claim-by-claim adjudication, and management is right that most Medicare claims are decided this way. “For the first time, Medicare beneficiaries nationwide have fully reimbursed access to our groundbreaking EsoGuard test.” — Lishan Aklog, Chairman and Chief Executive Officer · 2026-11-12 The logical consequence is that the MolDx LCD — the single obsession of four prior calls — is now optional. It still ranks near the top of the company's keyword set this quarter, but it is discussed as a parallel track and a backlog artifact rather than the gating item. That is the real news buried under the headline: a company that spent years waiting on one regulator quietly stopped needing it. The questions that followed were about Medicare population targeting and sales-force productivity, not about Washington.

Recognition is the actual business story

The revenue line is where the breakthrough confronts accounting. McGrath laid out the arithmetic plainly:

we have now performed more than 50,000 EsoGuard tests since inception, reflecting more than $140 million billings. Against approximately $16 million collected to date.

Dennis McGrath, Chief Financial Officer · 2026-11-12
That is the whole thesis in two numbers. The quarter itself recognized $1.2 million against roughly $7.9 million of billable value — about 15% realization, unchanged in structure if better in quality (average insurance allowable rose to $1,700 from $1,420). The sequential revenue decline was almost entirely direct contracting timing: 517 contracted tests in Q2 versus 60 in Q3. Medicare changes this because Novitas claims are now "predictable enough to consistently recognize upon report delivery," converting a cash-basis-like model into something closer to accrual for half the addressable market. The volume datapoint is the one that matters most: more than 1,800 tests in October alone, a monthly record, against 2,870 for the entire third quarter. Medicare volume in October already hit ~70% of the full prior quarter. Receivables to revenue has already climbed to roughly 72% — visible evidence that the recognition change is underway.

A 15%-realization company at 37x sales

The unit economics are genuinely good and management is not overselling them: “the next patient in the door contributes about 90%.” — Dennis McGrath, Chief Financial Officer · 2026-11-12 The device costs under $60, processing roughly $120. Against a $1,940 Medicare rate, the incremental margin is close to software-like. The problem is the denominator. Total revenue on the last filed quarter was about $2 million, up 25% year over year, and the just-reported September quarter came in at $1.2 million. Against that, Price to revenue sits near 37x, and gross margin is a thin 3.7%. Burn was $10.2 million in Q3, the lowest of four quarters, against average recent burn of $11.6 million. Cash of $18 million plus the October $15 million Series C gives roughly $33 million pro forma — call it three quarters of runway at the current pace, before any Medicare revenue ramp. And the capital structure is the quiet tax on all of it. The Series C converted at just over 35 cents, resetting the secured notes' conversion price from $1.00, and yields about 42.6 million shares. Current share count is roughly 207 million; fully diluted is about 330 million. Series C is now one of the company's higher-momentum keywords for a reason investors do not love.

The tape already voted — against

This is a company-unique story with no echo anywhere else in the market context: no global theme cluster, no other reporting company, no sector wave. Which makes the price action the honest referee. The stock is down 58% over 90 days, more than 60% below its July peak, having run up nearly 100% over a six-week stretch and then given back about half. That pattern — spike, then collapse into a genuinely good headline — is the classic signature of dilution plus a realization-rate discount, not of a broken test. Free cash flow is still running around negative $11 million a quarter. The tests are real. The Medicare payment is real, and management's claim that it is "the single most important development in the company's commercial history" is defensible. But Lucid has not yet become a revenue company — it has become a company with a functioning pathway to one. Until realized revenue closes meaningfully on that $140 million billing installed base, the equity remains a call option on execution, written against 330 million fully diluted shares.